Literature DB >> 15452242

Multiple epitopes in the murine cytomegalovirus early gene product M84 are efficiently presented in infected primary macrophages and contribute to strong CD8+-T-lymphocyte responses and protection following DNA immunization.

Ming Ye1, Christopher S Morello, Deborah H Spector.   

Abstract

We previously demonstrated that after vaccination of BALB/c mice with DNA encoding murine cytomegalovirus (MCMV) IE1 or M84, a similar level of protection against MCMV infection was achieved. However, the percentage of antigen-specific CD8(+) T cells elicited by IE1 was higher than that by M84 as measured by intracellular cytokine staining when splenocytes were stimulated with an epitope peptide (M. Ye at al., J. Virol. 76:2100-2112, 2002). We show here that after DNA vaccination with M84, a higher percentage of M84-specific CD8(+) T cells was detected when splenocytes were stimulated with J774 cells expressing full-length M84. When the defined M84 epitope 297-305 was deleted, the mutant DNA vaccine was still protective against MCMV replication and induced strong M84-specific CD8(+)-T-cell responses. The M84 gene was subsequently subcloned into three fragments encoding overlapping protein fragments. When mice were immunized with each of the M84 subfragment DNAs, at least two additional protective CD8(+)-T-cell epitopes were detected. In contrast to strong responses after DNA vaccination, M84-specific CD8(+)-T-cell responses were poorly induced during MCMV infection. The weak M84-specific response after MCMV infection was not due to poor antigen presentation in antigen-presenting cells, since both J774 macrophages and primary peritoneal macrophages infected with MCMV in vitro were able to efficiently and constitutively present M84-specific epitopes starting at the early phase of infection. These results indicate that antigen presentation by macrophages is not sufficient for M84-specific CD8(+)-T-cell responses during MCMV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452242      PMCID: PMC521820          DOI: 10.1128/JVI.78.20.11233-11245.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Macrophages escape inhibition of major histocompatibility complex class I-dependent antigen presentation by cytomegalovirus.

Authors:  H Hengel; U Reusch; G Geginat; R Holtappels; T Ruppert; E Hellebrand; U H Koszinowski
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).

Authors:  R Holtappels; J Podlech; N K Grzimek; D Thomas; M F Pahl-Seibert; M J Reddehase
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype.

Authors:  Rafaela Holtappels; Doris Thomas; Jürgen Podlech; Matthias J Reddehase
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Early gene m18, a novel player in the immune response to murine cytomegalovirus.

Authors:  Rafaela Holtappels; Natascha K A Grzimek; Doris Thomas; Matthias J Reddehase
Journal:  J Gen Virol       Date:  2002-02       Impact factor: 3.891

5.  Two overlapping subdominant epitopes identified by DNA immunization induce protective CD8(+) T-cell populations with differing cytolytic activities.

Authors:  F Rodriguez; M K Slifka; S Harkins; J L Whitton
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65).

Authors:  C S Morello; L D Cranmer; D H Spector
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  Processing and presentation of murine cytomegalovirus pORFm164-derived peptide in fibroblasts in the face of all viral immunosubversive early gene functions.

Authors:  Rafaela Holtappels; Natascha K A Grzimek; Christian O Simon; Doris Thomas; Doris Dreis; Matthias J Reddehase
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

8.  Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication.

Authors:  Christopher S Morello; Ming Ye; Deborah H Spector
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  Strong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challenge.

Authors:  Ming Ye; Christopher S Morello; Deborah H Spector
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

10.  The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL but does not alter the immunodominance of the M45-specific CD8 T cell response in vivo.

Authors:  Marielle C Gold; Michael W Munks; Markus Wagner; Ulrich H Koszinowski; Ann B Hill; Steven P Fling
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

View more
  9 in total

1.  Guinea pig cytomegalovirus GP84 is a functional homolog of the human cytomegalovirus (HCMV) UL84 gene that can complement for the loss of UL84 in a chimeric HCMV.

Authors:  A McGregor; K Y Choi; M R Schleiss
Journal:  Virology       Date:  2010-11-20       Impact factor: 3.616

Review 2.  CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model.

Authors:  Rafaela Holtappels; Verena Böhm; Jürgen Podlech; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2008-03-15       Impact factor: 3.402

3.  Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.

Authors:  Christopher S Morello; Ming Ye; Stephanie Hung; Laura A Kelley; Deborah H Spector
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 4.  Parameters determining the efficacy of adoptive CD8 T-cell therapy of cytomegalovirus infection.

Authors:  Stefan Ebert; Jürgen Podlech; Dorothea Gillert-Marien; Kerstin M Gergely; Julia K Büttner; Annette Fink; Kirsten Freitag; Doris Thomas; Matthias J Reddehase; Rafaela Holtappels
Journal:  Med Microbiol Immunol       Date:  2012-09-13       Impact factor: 3.402

5.  Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting.

Authors:  Marcus-Folker Pahl-Seibert; Markus Juelch; Jürgen Podlech; Doris Thomas; Petra Deegen; Matthias J Reddehase; Rafaela Holtappels
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

7.  Subdominant CD8 T-cell epitopes account for protection against cytomegalovirus independent of immunodomination.

Authors:  Rafaela Holtappels; Christian O Simon; Michael W Munks; Doris Thomas; Petra Deegen; Birgit Kühnapfel; Torsten Däubner; Simone F Emde; Jürgen Podlech; Natascha K A Grzimek; Silke A Oehrlein-Karpi; Ann B Hill; Matthias J Reddehase
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

8.  DNA immunization using highly conserved murine cytomegalovirus genes encoding homologs of human cytomegalovirus UL54 (DNA polymerase) and UL105 (helicase) elicits strong CD8 T-cell responses and is protective against systemic challenge.

Authors:  Christopher S Morello; Laura A Kelley; Michael W Munks; Ann B Hill; Deborah H Spector
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

9.  Reconstitution of CD8 T Cells Protective against Cytomegalovirus in a Mouse Model of Hematopoietic Cell Transplantation: Dynamics and Inessentiality of Epitope Immunodominance.

Authors:  Rafaela Holtappels; Niels A W Lemmermann; Jürgen Podlech; Stefan Ebert; Matthias J Reddehase
Journal:  Front Immunol       Date:  2016-06-14       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.